First, we treated non-tumor-bearing, wild-type mice with apilimod, a potent and specific PIKfyve inhibitor that has been studied in many cell types and evaluated in Phase II clinical trials.35,51-60 Next, we performed a global assessment of immune cells enriched from spleens. This evidence concerns the gene PIKFYVE and neoplasm.